Vanda Pharmaceuticals (VNDA) Consolidated Net Income (2016 - 2025)
Historic Consolidated Net Income for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to -$22.6 million.
- Vanda Pharmaceuticals' Consolidated Net Income fell 32422.99% to -$22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.2 million, marking a year-over-year decrease of 41384.87%. This contributed to the annual value of -$18.9 million for FY2024, which is 85328.82% down from last year.
- Vanda Pharmaceuticals' Consolidated Net Income amounted to -$22.6 million in Q3 2025, which was down 32422.99% from -$27.2 million recorded in Q2 2025.
- Over the past 5 years, Vanda Pharmaceuticals' Consolidated Net Income peaked at $9.6 million during Q2 2021, and registered a low of -$29.5 million during Q1 2025.
- For the 5-year period, Vanda Pharmaceuticals' Consolidated Net Income averaged around -$3.0 million, with its median value being $180000.0 (2023).
- In the last 5 years, Vanda Pharmaceuticals' Consolidated Net Income soared by 185646.26% in 2021 and then plummeted by 305777.78% in 2024.
- Quarter analysis of 5 years shows Vanda Pharmaceuticals' Consolidated Net Income stood at $7.1 million in 2021, then dropped by 2.96% to $6.9 million in 2022, then crashed by 134.71% to -$2.4 million in 2023, then crashed by 105.44% to -$4.9 million in 2024, then plummeted by 359.81% to -$22.6 million in 2025.
- Its Consolidated Net Income stands at -$22.6 million for Q3 2025, versus -$27.2 million for Q2 2025 and -$29.5 million for Q1 2025.